PP
BCAB icon

PDT Partners’s BioAtla BCAB Stock Holding History

PDT Partners’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-490
Closed -$202K – 580
2022
Q4 		$202K Hold
490
– – 0.03% 537
2022
Q3 		$189K Sell
490
-1,547
-76% -$506K 0.03% 733
2022
Q2 		$290K Buy
2,037
+129
+7% +$20.5K 0.03% 750
2022
Q1 		$477K Buy
+1,908
New +$798K 0.04% 598
2021
Q4 		– Sell
-150
Closed -$220K – 869
2021
Q3 		$220K Buy
+150
New +$292K 0.02% 669

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PDT Partners's BCAB Position: Q1 2023 in Review

PDT Partners sold out of BioAtla (BCAB) in Q1 2023, closing a stake of 490 shares — an estimated $202K sold.

PDT Partners first reported a position in BCAB in Q3 2021 and held it in 5 quarters. The position peaked at $477K in Q1 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

  • PDT Partners reported no remaining BioAtla position as of Q1 2023 after selling out during the quarter.
  • PDT Partners sold 490 BioAtla shares in Q1 2023, an estimated $202K.
  • PDT Partners first reported a position in BioAtla in Q3 2021 and held it in 5 quarters.
  • PDT Partners's BioAtla position peaked at $477K in Q1 2022.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.